TSHA

Taysha Gene Therapies, Inc. (TSHA) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. The company's lead program, TSHA-102, is in development for the treatment of Rett syndrome. As of June 30, 2026, the company had an accumulated deficit of $800.3 million and expects to continue incurring significant operating losses.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue was $0 for the three and six months ended June 30, 2026, compared to $2.0 million and $4.3 million in the prior year periods. This is due to the full recognition of revenue from the Astellas collaboration agreements by December 31, 2025.
• Increased Operating Expenses: Research and Development (R&D) expenses increased significantly to $38.6 million (Q2) and $72.4 million (YTD) in 2026, compared to $20.1 million and $35.7 million in 2025. This increase is driven by BLA-enabling Process Performance Qualification (PPQ) manufacturing initiatives and higher clinical trial costs for the REVEAL and ASPIRE trials.
• Lease Termination Gain: The company recorded a net gain of $3.4 million in Q2 2026 resulting from the termination of its manufacturing facility lease in Durham, North Carolina. This gain offset a portion of operating expenses.
• Capital Raise: In June 2026, the company completed an underwritten public offering, raising approximately $215.6 million in net proceeds. This significantly bolstered liquidity, increasing cash balances from $319.8 million at year-end 2025 to $455.4 million.

Guidance, Outlook, and Risks

• Clinical Progress: The company has completed dosing in the REVEAL Part A (Phase 1/2) and REVEAL Part B (Pivotal) trials for TSHA-102. Data from Part A showed 100% of patients gained or regained at least one developmental milestone. The interim analysis for the pivotal trial is expected after six months of follow-up, with topline data anticipated in the first half of 2027.
• Regulatory Pathway: The company has received Breakthrough Therapy and RMAT designations from the FDA. It has aligned with the FDA on a BLA submission strategy that may utilize data from the REVEAL Part A trial. The company expects to complete its PPQ campaign in Q4 2026.
• Liquidity Outlook: Management believes current cash resources of $455.4 million are sufficient to fund operations into the second half of 2028. However, the company expects to continue incurring significant losses and will require additional financing for future commercialization and development.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure regulatory approval, and the need for future capital raises. The company is also subject to standard biotechnology risks regarding manufacturing scale-up and commercialization.

Investor Verification Checklist

• Cash Runway: Verify the $455.4 million cash balance and the management estimate of funding operations into late 2028 against current burn rates.
• Debt Obligations: Review the terms of the $50 million Trinity Term Loan, including the 11.50% interest rate, prepayment premiums, and the $1.64 million success fee derivative liability.
• Clinical Data: Scrutinize the independent rater assessments of the 12 patients in REVEAL Part A and the timeline for the REVEAL Part B interim analysis.
• Manufacturing: Confirm the status of the PPQ campaign and the commercial supply agreement with Catalent, Inc.
• Legal Proceedings: Note the termination of the SEC investigation in June 2026 and the status of the shareholder derivative lawsuit, which the special litigation committee recommended terminating.